Elrig

MAY 8, 2024

Giles Yeo is now a Professor of Molecular Neuroendocrinology and programme leader at the MRC Metabolic Diseases Unit in Cambridge and his research currently focuses on the influence of genes on feeding behaviour & body-weight. In addition, he is a fellow of Wolfson College, and Honorary President of the British Dietetic Association.

Drugs 59

Drugs Science Research Disease 59

sptlabtech

JUNE 9, 2023

The field of genomics has witnessed a revolutionary transformation, leading to a better understanding of health and disease, as well the emergence of personalized medicine to improve therapeutic outcomes. Book your tailored demo Do you want to learn how firefly can work for you?

Laboratories 98

Laboratories Molecular Biology DNA Engineering 98

Drug Target Review

MAY 3, 2024

This is especially true in domains such as protein structure, predictive binding kinetics, and even in larger systemic investigations like cell migration models or disease progression. Often you learn so much more from the mistakes and challenges of others when perfecting a specific technique or chasing down an investigative possibility.

Research 116

Research Science Cell Based Assays Disease 116

The Open Targets Blog

SEPTEMBER 21, 2023

It’s a multi-dimensional, cross-disciplinary problem, requiring an understanding of genetics, of disease biology, and of drug discovery factors. For example, there are often many potential targets you could consider developing a treatment against for a given disease; how do you choose between them?

Organic Chemistry 82

Organic Chemistry Process Chemistry Small Molecule Science 82

PLOS: DNA Science

NOVEMBER 16, 2023

The situation is a little like reading a book review or CliffsNotes (yes, they still exist) to get the main plot points (QTLs) compared to reading the entire book (the genome sequence). GBLUP sounds a little like presymptomatic genetic testing for a disease in humans.

DNA 98

DNA Science Disease Research 98

Advarra

FEBRUARY 28, 2023

Crumpler’s focus on the care of women and children and her dedication to research led her to publish “A Book of Medical Discourses” in 1883. Her book covered a wide range of health topics, including the impact of poverty, lack of education, and discrimination on the health outcomes of African American women and children.

Medical Schools 52

Medical Schools Laboratories Clinical Research Treatment 52

LifeSciVC

AUGUST 21, 2024

This is especially true for rare disease trials with so few patients or trials involving patients with numerous concomitant or life-threatening conditions. The decision to pursue a much larger immune-mediated disease for our lead program versus a smaller, niche indication was not hindered by manufacturability or scalability.

Clinical Trials 77

Clinical Trials Trials Disease Treatment 77

The Pharma Data

SEPTEMBER 8, 2020

The Japanese pharma firm is jettisoning the products as they no longer fit within its five key therapeutic areas of gastroenterology, rare diseases, plasma-derived therapies, oncology and neuroscience. The moves represent Takeda’s attempts to balance the books following its mammoth acquisition of Shire in 2018 for $62 billion.

Therapies 52

Therapies Production Disease Drugs 52

The Pharma Data

JANUARY 20, 2021

Nasdaq: DYN), a muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced the pricing of an underwritten public offering of 6,000,000 shares of its common stock at a public offering price of $28.00 WALTHAM, Mass., About Dyne Therapeutics.

Disease 52

Disease 52

Drug Target Review

DECEMBER 19, 2023

On the neurologic side, there are findings about neurotoxins and environmental contaminants showing correlations with a variety of neurologic diseases across the lifespan from children to adults. On the mental health side, there is anxiety around climate change – Eco-Anxiety.

Science 115

Science Bioethics International Research 115

Sygnature Discovery

OCTOBER 9, 2024

Therapeutic areas of expertise include oncology, inflammation and immunology, neuroscience, metabolic diseases, infectious diseases, fibrotic diseases, and more. Offering 2,900 scientific journals and reference books, such as Cell Press and The Lancet, we leverage trusted content and innovative AI-driven technologies.

Science 52

Science Disease Research Pharmaceuticals 52

Drug Target Review

OCTOBER 24, 2024

Janette Thomas leads a small biotech company (Five Alarm Bio) 1 on a mission to develop drugs targeting the chronic diseases associated with ageing. Her company’s focus includes dementia, muscle wasting, and chronic wounds – diseases that disproportionately affect the elderly. Reference 1 Five Alarm Bio. cited 2024 Oct 17].

Cell Based Assays 52

Cell Based Assays Science Disease Doctors 52

The Pharma Data

DECEMBER 7, 2020

Download Pharma IQ ’s short guide to receive four key takeaways to support supply chain frameworks in a state of emergency – from disease outbreaks, such as the Covid-19 pandemic, to natural disasters. Book your place at the Temperature Control and Logistics forum 2021 and continue to build your professional network virtually. .

Production 52

Production Disease 52

The Pharma Data

JANUARY 12, 2021

13, 2021 (GLOBE NEWSWIRE) — Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) (“Tiziana” or the “Company”), a biotechnology company focused on innovative therapeutics for oncology, inflammation, and infectious diseases, announces the appointment of Dr Neil Graham MBBS, MD, MPH as Chief Medical Officer. NEW YORK and LONDON, Jan.

Science 52

Science Clinical Development Disease Production 52

Drug Target Review

JUNE 12, 2023

He also pioneered applications of deep learning technologies for prediction of human biological age using multiple data types, and transferred learning from aging into disease, target identification, and signalling pathway modelling.

Metabolic Stability 92

Metabolic Stability Clinical Trials Small Molecule Therapies 92

The Pharma Data

DECEMBER 8, 2020

Citigroup, Evercore ISI and Mizuho Securities are acting as joint book-running managers for the offering. is a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and autoimmune diseases.

Marketing 52

Marketing Disease Therapies 52

The ChEMBL-og

JUNE 13, 2023

The dataset is also available from the ChEMBL - Neglected Tropical Disease archive ([link] Literature data from EUbOPEN Chemogenomic Library (src_id = 65): 2,842 bioactivity measurements have been extracted from primary literature by the SGC consortium to complement their Chemogenomic library (src_id = 55).

FDA Approval 97

FDA Approval Pharmacokinetics International Production 97

The Pharma Data

OCTOBER 23, 2020

Elmaleh’s research has yielded compounds with potential in oncology, heart disease and neurodegenerative conditions, BOSTON, MA, October 23, 2020 /24-7PressRelease/ — Marquis Who’s Who, the world’s premier publisher of biographical profiles, is proud to honor David.

Organic Chemistry 52

Organic Chemistry Clinical Trials Science Pharmaceuticals 52

Elrig

AUGUST 13, 2024

space is limited on a first-come-first-served basis 3 October, 1pm 2pm The Learning Zone Book at consultation ECP Awards We are no longer accepting applications for the ECP awards. Kirsty Smitten Award: Celebrate your impact in early drug discovery through science, leadership, and collaboration.

Drugs 52

Drugs Science International Marketing 52

The Pharma Data

JANUARY 7, 2021

Jefferies is acting as the sole book-running manager for the offering and Oppenheimer & Co. Cerecor is a biopharmaceutical company focused on becoming a leader in the development and commercialization of treatments for rare and orphan diseases. ROCKVILLE, Md. and CHESTERBROOK, Pa., 07, 2021 (GLOBE NEWSWIRE) — Cerecor Inc.

Clinical Development 52

Clinical Development Disease Treatment FDA Approval 52

The Pharma Data

AUGUST 7, 2020

The ARM report also showcased robust pipelines of therapies targeting indications in cancers, infectious diseases and inherited disorders. Download the e-book here. These concurrent trials have the potential to yield significant and comprehensive clinical data.”. Source link.

Clinical Trials 52

Clinical Trials Trials Packaging Therapies 52

The Pharma Data

OCTOBER 15, 2020

Morgan, Jefferies and Piper Sandler are acting as the joint book-running managers for the offering. is a clinical stage biopharmaceutical company that was founded in 2018 with the mission to become a world leader in the treatment of viral infections and liver diseases. Cantor is acting as a lead manager for the offering.

Disease 40

Disease Drug Development Therapies Treatment 40

The Pharma Data

JANUARY 24, 2021

Professor of Medicine, Section of Infectious Diseases and Global Health and director of the Duchossois Family Institute at the University of Chicago, has joined its scientific advisory board. His research focuses on the role of the microbiome in immune defense and disease resistance. “We About Diversigen Inc.

Research 40

Research Bioinformatics Laboratories International 40

Elrig

SEPTEMBER 19, 2023

The city is well renowned for disease and healthcare research, too. Ronald Ross, a professor at the University and a pioneer in malaria research, discovered that mosquitos transmitted the disease , for example. Liverpool has a deep scientific history, with the University of Liverpool being associated with nine Nobel Laureates.

Drugs 59

Drugs Disease Therapies Research 59

Drug Target Review

FEBRUARY 14, 2025

The KEGG Pathway database provides insights into metabolic pathways, genetic interactions and disease mechanisms, which are crucial for understanding how a dataset can inform our understanding of complex biological phenomena such as signal transduction, cell proliferation, or immune responses.

Drugs 52

Drugs Research Immune Response Science 52

Drug Target Review

OCTOBER 14, 2024

His current role at Mironid focuses on developing treatments for rare genetic kidney diseases, and his insights reveal the challenges and potential of integrating advanced technologies like artificial intelligence (AI) into the drug discovery process. He has published several papers and two books and has twelve issued patents.

Science 52

Science Pharmaceutical Companies Drug Development Pharmaceuticals 52

The Pharma Data

DECEMBER 1, 2020

Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced the pricing of an underwritten public offering of 10,256,411 shares of its common stock, offered at a public offering price of $9.75 are acting as joint book-running managers for the offering.

Therapies 52

Therapies Disease Production Marketing 52

The Pharma Data

DECEMBER 9, 2020

” Mosconi, who has written books about the science of food and the brain, said many people have misconceptions about what “proper food” might be. years of protection against the development of biomarkers for Alzheimer’s disease. “This is not what most research shows,” she said.

Science 52

Science Hospitals Disease Research 52

The Pharma Data

DECEMBER 3, 2020

LLC, SVB Leerink and Stifel are acting as joint book-running managers for the offering. The gross proceeds to Silverback from the offering, before deducting the underwriting discounts and commissions and offering expenses, are expected to be $241.5 The offering is expected to close on December 8, 2020, subject to customary closing conditions.

Treatment 40

Treatment Disease Marketing 40

The Pharma Data

JANUARY 19, 2021

are acting as joint book-running managers for the offering. Based on its unique ability to elucidate regulatory regions of the genome, Syros aims to develop medicines that provide a profound benefit for patients with diseases that have eluded other genomics-based approaches. Cowen and Piper Sandler & Co.

Small Molecule 52

Small Molecule Clinical Trials Pharmaceuticals Virus 52

NIH Director's Blog: Drug Discovery

MAY 9, 2019

Similarly, when the complete human genome sequence was revealed for the first time in 2003, commentators (including me) referred to this as the moment where the book of life for humans was revealed. When NIH’s Marshall Nirenberg and his colleagues cracked the genetic code in 1961, it was called the solution to life’s greatest secret.

Engineering 52

Engineering Regulations Science Therapies 52

The Pharma Data

JANUARY 13, 2021

(Nasdaq: ALDX) (Aldeyra), a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases, today announced the pricing of an underwritten public offering of 6,842,106 shares of its common stock at a public offering price of $9.50

Clinical Trials 40

Clinical Trials Disease Therapies Trials 40

Vial

FEBRUARY 19, 2024

At the time, chronic lymphocytic leukemia was really a horrible disease, and only 57 percent of patients had a response. They eventually succumbed to the disease for multiple reasons. I don’t know if you’ve read that book, but it’s a very important book, where you always do your best.

Small Molecule 52

Small Molecule Therapies Treatment Science 52

The Pharma Data

DECEMBER 15, 2020

Nasdaq: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced the pricing of an underwritten public offering of 3,725,000 shares of its common stock at a public offering price of $21.50 About Ocular Therapeutix, Inc.

FDA Approval 40

FDA Approval Disease Therapies Clinical Development 40

The Pharma Data

DECEMBER 16, 2020

Nasdaq: GMDA), an advanced cell therapy company committed to cures for blood cancers and serious hematologic diseases, today announced the launch of a follow-on public offering of its ordinary shares. and JMP Securities LLC are acting as joint book-running managers for this offering. Piper Sandler & Co., Evercore Group L.L.C.

Therapies 40

Therapies Clinical Development Disease Marketing 40

The Pharma Data

OCTOBER 15, 2020

BofA Securities, Jefferies and Raymond James are acting as joint book-running managers for the offering. It is advancing its pipeline to address several diseases across therapeutic categories including eye care, dermatology, and other diseases with high, unmet needs. Tarsus Pharmaceuticals, Inc.

Pharmaceuticals 40

Pharmaceuticals Marketing Treatment Disease 40

The Pharma Data

DECEMBER 15, 2020

are acting as joint book-running managers for the offering. Arvinas is a clinical-stage biopharmaceutical company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins.

Targeted Protein Degradation 40

Targeted Protein Degradation Engineering Clinical Trials Disease 40